ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Winner

ACADIA Pharmaceuticals ( ACAD) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, ACADIA Pharmaceuticals rose $1.79 (9.7%) to $20.28 on average volume. Throughout the day, 5,425,644 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 3,676,900 shares. The stock ranged in a price between $18.45-$20.43 after having opened the day at $18.67 as compared to the previous trading day's close of $18.49. Other companies within the Drugs industry that increased today were: ImmunoCellular Therapeutics ( IMUC), up 15.1%, Ambit Biosciences ( AMBI), up 11.6%, Neostem ( NBS), up 9.4% and Nymox Pharmaceutical Corporation ( NYMX), up 9.2%.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.6 billion and is part of the health care sector. Shares are up 299.1% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

On the negative front, Mast Therapeutics ( MSTX), down 35.9%, Tranzyme ( TZYM), down 6.9%, Biostar Pharmaceuticals ( BSPM), down 6.2% and Prima Biomed ( PBMD), down 6.1% , were all laggards within the drugs industry with Alexion Pharmaceuticals ( ALXN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Tesla Jumps on Model 3 Expansion Hopes, China Trade Truce

Tesla Jumps on Model 3 Expansion Hopes, China Trade Truce

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO